IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.